YUNLIN, TAIWAN – APR 22, 2026 – AeproMED Innovation Co., Ltd. (AeproMED), a leader in integrated inhalation drug delivery platforms, and National Taiwan University Hospital Yunlin Branch (NTUH Yunlin) have officially signed a Memorandum of Understanding (MOU) to collaborate on the "Clinical Guidelines for Chest Inhalation and Smart Drug Delivery Applications". This strategic partnership focuses on addressing the clinical pain points of patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) by transitioning high-concentration antibiotic inhalation therapy from clinical institutions to the home environment.

Addressing Systemic Bottlenecks in Respiratory Care

The current healthcare system faces significant structural limitations, including high acute bed occupancy rates (exceeding 85%) and severe nursing shortages. Patients suffering from NCFB often fall into a "vicious cycle" of infection, inflammation, and irreversible airway damage. Moderate-to-severe patients typically experience 1.5 to 3 acute exacerbations annually, placing a heavy burden on medical resources.

"Traditional inhalation treatments are highly dependent on hospital settings, leaving a 'care black box' once the patient returns home due to a lack of real-time monitoring," said Vicky Chang, CEO of AeproMED. "Through this collaboration, we will develop clinical guidelines for both acute and chronic respiratory conditions and integrate smart home-based monitoring to ensure continuous care".

Empowering Home Care with AFDT™ and Smart Monitoring

The success of home-based antibiotic therapy relies on dosing stability and patient adherence. AeproMED’s flagship device, the NEBreath™ vibrating mesh nebulizer, features proprietary AFDT™ (Aerosol Fluid Dynamics Technology), which dynamically balances nebulization performance to ensure consistent aerosol output and particle size, even as the device mesh ages.

Performance data indicates that NEBreath™ is highly efficient for delivering high-concentration antibiotics, with an average treatment time of just 7.5 minutes and significantly lower drug residue compared to competitors. Combined with DSMT™ (Data Synchronization Monitoring Technology), medical professionals can track medication behavior and physiological trends via a cloud-based dashboard, enabling proactive home management.

Data-Driven Evidence for Precision Medicine and Reimbursement

The partnership aims to achieve more than just clinical validation; it seeks to establish new industry standards. AeproMED and NTUH Yunlin plan to:

• Update Clinical Guidelines: Provide local evidence-based data to the Taiwan Society of Pulmonary and Critical Care Medicine to update treatment protocols for NCFB.
• Seek NHI Reimbursement: Submit a formal proposal for a dedicated National Health Insurance (NHI) reimbursement code for "Home Nebulized Antibiotic Therapy for Bronchiectasis".
• Shorten the Translational Gap: Leverage the AIRHYPER™ Platform to bridge the gap between lab-based R&D and real-world clinical application.

With over 30 global patents and an ISO 13485-certified manufacturing facility in the Hsinchu Biomedical Science Park, AeproMED is committed to building a continuous, stable, and sustainable home-care network for respiratory patients worldwide.